Member Info for calisto

the rise this week despite RICS's best efforts to kick the sector in the knackers. Its high time the FCA looked into the impact this "survey: data has on the market and who trades on it.

We will see it from the trading ahead of the release as we will be the last to find out.

seems to be picking up and more stock being looked fort it would appear

since 12.39?

You have left Scotland out. I venture they are probably up there with Ireland. The delicious irony is, is that either Veradkar put up a hard border or gives way on the backstop. Its easy to see why he is bricking it as he will go down in history of having screwed the Irish economy and knocked back the peace process. poor Leo was played like a kipper by Barnier and his UK remainer chums in parliament.

precisely! 117 please. thank you .best calisto

I see my name has been removed from the list. I think you will find I have paid up. best calisto

Spot on. The man is utterly loathsome and bereft of any democratic notions utilising a mob of "activist thugs" to position him into a potential position of authority. There is still for the time being at least a more principled element within the labour party which may put up a bit of a struggle to resist a complete takeover by the unelected thugs and their Trade Union paymasters.

Seems very low too me given the cost of getting an AB to the market let alone a new one which will have many future applications and a lengthy protected revenue stream.

She has that in common with JC

we will see the same as yesterday as the AT's continue to use this share as their hole in the wall.

slip meant AT puppeteers

why they should stop anywhere. the shares will be picked up by momentum traders and nervous holders. The MM's know that so its a free meal every time for them

the analysts on the call yesterday. It would have been an easy question to ask JAK in view of the SP response to yesterday's trail update.

Agreed. But then why would the restriction be imposed in the US? It strikes me the FDA is well aware that most current AB's and their offshoots designated as "new" are becoming less and less effective and as such their effective life will get less and less and the resistance continues to build. Clearly work needs to be done to gain wider approval but then that should be less onerous a task once the drug has entered a clinical setting. Fingers crossed Iclaprim is the drug we all hope that it is for any number of reasons not least tat we are all up against now following years of procrastination and over use. We test new compounds against the prevailing " gold standard" for superior efficacy with seemingly scant regard of the fact that the "gold standard's" effectiveness as the go to treatment is already becoming questionable. We now have an MRSA epidemic and now super gonorrhoea.

That number has been around for a long time and has been presented on this board on numerous occasions I know. the analysis sees Iclaprim as a one trick pony only to be used on really impaired patients presenting a very specific condition. We have here a new class of antibiotic that is going up against AB's that are growing less and less effective as resistance continues to build up. We have a crisis in our hospitals with MRSA taking lives daily in increasing numbers. Surgical procedures are being heavily compromised as a result. To some extent management has been to blame as they have always presented a narrow focus. But the Zacks analysis which others seems to have used as ground work only really takes a very narrow view giving little or no thought to the other applications that have already been hinted at nor the exclusivity protection granted. If the drug is safe, well tolerated and more effective than the comparatives it has been tested against in its journey to the market so far there seems little sense in restricting its use to a very narrow setting in the longer term.

where does the $500m peak sales come from?

Interesting point. How do you get to $0.5bn?

by any means. Odd that less than 0.1% of the shares traded can see a 40% decline in the value of the company. To me this indicates that institutional shareholders seem to be sitting on their hands for the time being. Furthermore nobody asked the credibility question during the Q&A.

At 1pm so be brave and ask the questions